A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.


The efficacy, tolerability, and safety of LY2216684, a highly selective norepinephrine reuptake inhibitor, were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose LY2216684 6-18 mg once daily (N = 250) with placebo (N = 245) for 10 weeks acute therapy followed by 1 year LY2216684… (More)
DOI: 10.1016/j.jpsychires.2011.03.014


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.